Propanc Biopharma, Inc. — Form S-1
Filed July 17, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 22/100
What the filing says
Propanc Biopharma filed Form S-1 on July 17, 2026 to register 2,500,000 common shares (par value $0.001) issuable upon conversion of Series C Preferred Stock held by a selling stockholder. Legal counsel (Brunson Chandler Jones, PLLC) opined that upon conversion, the shares will be validly issued, fully paid, and non-assessable. The filing includes auditor consent from Salberg Company, P.A. for financial statements covering fiscal years ended June 30, 2025 and 2024, with a noted May 18, 2026 reverse stock split.
Why this rating
Routine S-1 registration mechanics for preferred conversion. At $48K market cap, 2.5M shares are likely immaterial to total cap structure and represent standard legal compliance filing.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.